Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | MGLL | Q99685 | 6/20 | 0.43 |
| ▸ | GLS | O94925 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14148705 | 0.92 | MGLL (0.46) | EPHX2MGLLGLSGPR119 | |
| SCHEMBL4130775 | 0.89 | MGLL (0.43) | MGLLGLSROCK1 | |
| SCHEMBL13849609 | 0.85 | ROCK1 (0.44) | EPHX2GLSROCK1 | |
| SCHEMBL23301876 | 0.77 | EPHX2 (0.45) | EPHX2MGLLGPR119 | |
| SCHEMBL12922895 | 0.76 | GLS (0.61) | EPHX2GLSROCK1 | |
| SCHEMBL13849603 | 0.76 | EPHX2 (0.39) | EPHX2GPR119 | |
| SCHEMBL17324842 | 0.76 | MGLL (0.70) | MGLLGPR119 | |
| SCHEMBL2766618 | 0.75 | GPR119 (0.58) | GPR119ROCK1 | |
| SCHEMBL30696599 | 0.75 | EPHX2 (0.53) | EPHX2GPR119 | |
| Acetic Acid SCHEMBL29910540 | 0.75 | EPHX2 (0.43) | EPHX2MGLLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090118263-A1 | Novel Adenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1939202-A1 | NOVEL ADENINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118263-A1 | Novel Adenine Compound | ADORA1, ADORA2A, ADORA3 | EPHX2 3275/4885MGLL 4039/4885GLS 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.